Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout
admin 19th October 2018 Uncategorised 0Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market—and hoping to add blockbuster sales to a portfolio that’s at the heart of Takeda’s $62 billion buyout.
More: Panel backing for key Shire drug beefs up Takeda's case for its B buyout
Source: fierce